Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/22/2025

Treatment of Insomnia with Mirtazapine and Trazodone

Clinical Guidelines and Recommendations

  • The American Academy of Sleep Medicine (AASM) recommends that sedative antidepressants, such as trazodone and mirtazapine, be considered only as a third option for treating insomnia, after short-to-intermediate-acting benzodiazepine receptor agonists and ramelteon 2
  • The Department of Veterans Affairs/Department of Defense (VA/DOD) guidelines explicitly suggest against the use of trazodone for the treatment of chronic insomnia 1
  • These medications are not approved by the FDA specifically for insomnia, and their efficacy for this indication is not well established 3

Treatment Approach

  • For the treatment of insomnia, cognitive behavioral therapy for insomnia (CBT-I) should be considered as the first line of treatment before pharmacotherapy 2, 1
  • If pharmacotherapy is necessary, short-to-intermediate-acting benzodiazepine receptor agonists (such as zolpidem, eszopiclone, zaleplon) or ramelteon are recommended as the first choice 2, 4

Special Considerations

  • In elderly patients, dose adjustment to lower values is recommended due to the increased risk of adverse effects 3
  • The use of antidepressants for insomnia should be accompanied by regular reassessments of efficacy and adverse effects 2

REFERENCES

1

clinical guideline for the evaluation and management of chronic insomnia in adults. [LINK]

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2008

3

clinical guideline for the evaluation and management of chronic insomnia in adults. [LINK]

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2008

4

Insomnia Treatment Guidelines [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025